Inactive Instrument
Checkmate Pharmaceuticals, Inc. Stock
Stocks
CMPI
US1628181083
Biotechnology & Medical Research
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 2018-12-11 | |
Robert Landry
DFI | Director of Finance/CFO | 62 | 2022-05-30 |
James Wooldridge
CTO | Chief Tech/Sci/R&D Officer | 60 | 2019-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Nouhad Husseini
BRD | Director/Board Member | - | 2022-05-30 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 5/31/22 | Issuer sale | Director | 36,778 | 0.1700% | ||
| 5/31/22 | Issuer sale | Chief Financial Officer | 278,480 | 1.2874% | ||
| 5/31/22 | Issuer sale | Chief Executive Officer | 279,437 | 1.2919% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +0.38% | - | - | 231M | |
| +0.66% | +1.83% | +47.32% | +97.63% | 69.18B | |
| -1.19% | -1.92% | +34.57% | +73.08% | 62B | |
| +2.22% | -4.83% | -15.32% | +360.65% | 26.19B | |
| +1.46% | +2.25% | +28.84% | +13.76% | 25.75B | |
| -0.89% | -2.34% | -3.46% | -15.24% | 24.29B | |
| +2.84% | +3.61% | +24.60% | -17.13% | 19.84B | |
| 0.00% | -10.41% | +171.96% | +298.75% | 15.65B | |
| -0.57% | -1.37% | -4.53% | +825.13% | 13.88B | |
| -0.39% | -4.24% | -9.86% | +483.04% | 14.09B | |
| Average | +0.41% | -2.05% | +30.46% | +235.52% | 30.1B | |
| Weighted average by Cap. | +0.33% | -1.18% | +31.95% | +159.89% |
Employees
31
